Aurobindo Pharma's New Jersey Facility Receives 10 Observations from USFDA After Inspection

26 Dec 2023 , 11:29 AM

The USFDA conducted a pre-approval inspection at Aurobindo Pharma’s facility in New Jersey. The inspection targeted the new injectable facility of Eugia US Manufacturing LLC in East Windsor, from December 11 to December 22, 2023.

USFDA issued 10 observations based on the inspection. Aurobindo Pharma will respond to the observations within the stipulated time.

The plant subject to inspection has not yet started commercial operations. Aurobindo Pharma reported an 85 % YoY increase in consolidated net profit to Rs 757 crore for July-September.

Revenue showed a robust growth of 25.7 %, reaching Rs 7,219.4 crore. On December 22, Aurobindo Pharma’s shares closed down almost 3 % at Rs 1066.40 apiece.

For feedback and suggestions, write to us at [e-mail]